Legend Biotech (LEGN) to Release Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Legend Biotech to post earnings of ($0.17) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:00 AM ET.

Legend Biotech Trading Up 6.9%

NASDAQ LEGN opened at $18.97 on Friday. Legend Biotech has a 12 month low of $16.24 and a 12 month high of $45.30. The company has a current ratio of 2.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.17. The stock’s fifty day moving average price is $19.60 and its 200-day moving average price is $26.76. The stock has a market cap of $3.50 billion, a P/E ratio of -29.18 and a beta of 0.07.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Barclays cut their price objective on shares of Legend Biotech from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 4th. Oppenheimer began coverage on shares of Legend Biotech in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $75.00 target price on the stock. Morgan Stanley cut their price target on shares of Legend Biotech from $83.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, December 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Legend Biotech in a research report on Monday, December 29th. Finally, Raymond James Financial restated an “outperform” rating on shares of Legend Biotech in a report on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Legend Biotech has an average rating of “Moderate Buy” and an average target price of $55.08.

Hedge Funds Weigh In On Legend Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of LEGN. Invesco Ltd. grew its stake in shares of Legend Biotech by 4.4% in the fourth quarter. Invesco Ltd. now owns 13,710 shares of the company’s stock worth $298,000 after acquiring an additional 581 shares during the period. Parallel Advisors LLC lifted its position in Legend Biotech by 171.9% during the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after purchasing an additional 662 shares during the period. Fox Run Management L.L.C. boosted its holdings in Legend Biotech by 4.3% in the fourth quarter. Fox Run Management L.L.C. now owns 20,806 shares of the company’s stock worth $452,000 after purchasing an additional 863 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in Legend Biotech by 31.0% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 3,800 shares of the company’s stock worth $124,000 after purchasing an additional 900 shares during the period. Finally, Royal London Asset Management Ltd. raised its stake in Legend Biotech by 2.0% during the 2nd quarter. Royal London Asset Management Ltd. now owns 60,800 shares of the company’s stock valued at $2,158,000 after buying an additional 1,200 shares during the last quarter. Institutional investors own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.